A Triple-Modal Contrastive Learning Framework with Sequence, Graph, and 3D Features for Drug-Target Interaction Prediction
Not on the map. Why?
Abstract (arXiv)
Accurate prediction of drug-target interactions (DTI) is critical for drug discovery. Existing methods often rely on single-modal representations (e.g., sequences or graphs) or combine only two modalities, overlooking 3D structural features. To address this challenge, we propose TriMod-DTI, a triple-modal contrastive learning framework that incorporates 1D sequences, 2D graphs, and 3D structures of drugs and proteins, obtaining the universal and complementary feature representations for DTI prediction. We design a Feature Extractor to capture drug and target features across the three modalities, thereby enriching their representations. We further propose a triple-modal contrastive learning strategy to align different modal representations of the same drug or protein in the latent space. By constructing cross-modal positive and negative sample pairs, this approach enhances the model's discriminative ability. Experiments on three benchmark datasets demonstrate that TriMod-DTI outperforms state-of-the-art methods. The ablation studies validate the contributions of each modality. Moreover, case studies highlight its practical potential for DTI prediction and drug discovery.
Key facts. No citing papers in the map yet (data through 7 Oct 2026). Builds on 6 of its 23 references that are in the map. First posted on arXiv 28 May 2026.
Builds on
6 of 23 references.
References · 6
- 2017Attention Is All You Needcited by 59,932
- 2021Learning Transferable Visual Models From Natural Language Supervisioncited by 33,456
- 2016Semi-Supervised Classification with Graph Convolutional Networkscited by 11,282
- 2020Learning from Protein Structure with Geometric Vector Perceptronscited by 308
- 2017Topology Adaptive Graph Convolutional Networkscited by 112
- 2020MolTrans: Molecular Interaction Transformer for Drug Target Interaction Predictioncited by 63
Built on by
Not cited yet.